Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
Tel Aviv, Israel / Vancouver, Canada, May 19, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE:...
Pharmaceutical
Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
EDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial...
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023
Company to host conference call to discuss financial results and provide a corporate update on May 22, 2023 at 4:30...
Lucy Scientific Discovery Inc. Announces Sponsorship at the Psychedelic Science Conference June 19-25, 2023
VANCOUVER, British Columbia, May 19, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “the Company”) (NASDAQ: LSDI), a...
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec) for the Treatment of Dystrophic Epidermolysis...
Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or spinal cord injury
Submission based on data from the pivotal international Phase III CONTENT clinical program, also recently published in European Urology1CONTENT showed that...
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Treatment with CAN-3110 in arm A showed encouraging median overall survival rate at 11.8 months after a single injection. These...
SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
SIOUX FALLS, S.D., May 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company with a novel...
Ultragenyx to Present at the 2023 Barclays – Gene Editing & Gene Therapy Summit
NOVATO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development...
STRATA Skin Sciences Announces TheraClear®X Product Demonstration at Music City Scale Symposium for Cosmetic Advances and Laser Education
HORSHAM, Pa., May 19, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to...
Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development...
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
KT-253 is a novel, highly potent and selective heterobifunctional degrader of the MDM2 oncoprotein with a differentiated profile from small...
Reviva Pharmaceuticals Joins Webull Corporate Communications Service Platform
CUPERTINO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...
BBS-Bioactive Bone Substitutes Oyj: The subscription period for the second warrant series starts on 22 May 2023 – the subscription price is EUR 0.65 per share
BBS-Bioactive Bone Substitutes Oyj, Company release, 19 May 2023 at 12.00 p.m. EEST BBS-Bioactive Bone Substitutes Oyj: The subscription period...
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same...
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period...
Lucy Scientific Discovery Inc. Accelerates Psilocybin Access and Product Launch through a Strategic Partnership with TheraPsil
VANCOUVER, British Columbia, May 18, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “the Company”) (NASDAQ: LSDI), a...
BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting
NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical...
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
VANCOUVER, British Columbia, May 18, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional...
MiNK’s Novel FAP-CAR-iNKT Presented at ASGCT
FAP-CAR-IL-15 iNKT cell therapy (MiNK-215) promotes curative responses driving tumor elimination and immune infiltration in NSCLC modelsIND enabling studies underway;...